Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Abpro CorpABP · Entity 166815 | Director | May 10, 2018 | May 10, 2018 |
| KALA BIO, Inc.KALA · Entity 7964 | Director | June 12, 2018 | June 15, 2018 |
| Korro Bio, Inc.FREQ · Entity 6388 | Director | August 17, 2022 | August 19, 2022 |
| Lyra Therapeutics, Inc.LYRA · Entity 46837 | Director | May 05, 2020 | May 06, 2020 |
| Moderna, Inc.MRNA · Entity 2025 | Director | May 06, 2024 | May 07, 2024 |
| Rubius Therapeutics, Inc.RUBY · Entity 116417 | Director | October 14, 2019 | October 17, 2019 |
| SQZ Biotechnologies CoSQZ · Entity 112267 | 10% owner | October 29, 2020 | October 30, 2020 |
| Seer, Inc.SEER · Entity 6717 | Director | July 28, 2026 | July 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Abpro Corp
Report date May 10, 2018 · Filed May 10, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 253,439 |
Reported balance
Holding disclosure · report date 2018-05-10 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 253,439 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.16 · Expires 2027-07-14 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2018-05-10 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: Immediately exercisable, but subject to certain repurchase rights if the Reporting Person does not continue to serve as a director for up to three years following his February 12, 2017 appointment to the Issuer's board of directors. The Issuer's repurchase right with respect to 1/3 of the Reporting Person's shares will terminate following each full year of service on the Issuer's board of directors. |
Filing footnotes · ownership attribution and instrument terms
F1: Immediately exercisable, but subject to certain repurchase rights if the Reporting Person does not continue to serve as a director for up to three years following his February 12, 2017 appointment to the Issuer's board of directors. The Issuer's repurchase right with respect to 1/3 of the Reporting Person's shares will terminate following each full year of service on the Issuer's board of directors.
KALA BIO, Inc.
Report date June 12, 2018 · Filed June 15, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.73 · Expires 2028-06-11 | Direct | 12,960 |
Reported balance
After 2018-06-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-12 · Grant · Acquired 12,960 · Balance 12,960 F1: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on June 12, 2018 and vests in equal monthly installments until the one-year anniversary of the date of grant and will vest automatically as to 100% of the unvested portion of such option upon specified change in control events.
Korro Bio, Inc.
Report date August 17, 2022 · Filed August 19, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2030-06-10 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $18.63 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2031-06-16 | Direct | 14,846 |
Reported balance
After 2022-08-17 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-08-17 · Grant · Acquired 14,846 · Balance 14,846 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $10.14 · Expires 2031-06-16 | Direct | 0 |
Reported balance
After 2022-08-17 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-17 · Disposition to issuer · Disposed 14,846 · Balance 0 F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.
F2: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options.
F3: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders.
F4: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
F5: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders.
Lyra Therapeutics, Inc.
Report date May 05, 2020 · Filed May 06, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 15,167 |
Reported balance
After 2020-05-05 transaction · row 1
1 source rowRow 1 · 2020-05-05 · Conversion · Acquired 668 · Balance 15,167 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. |
| Series A-1/A Convertible Preferred StockSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-05-05 · Conversion · Disposed 23,057 · Balance 0 F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.
Moderna, Inc.
Report date May 06, 2024 · Filed May 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $122.13 · Expires 2034-05-06 | Direct | 7,557 |
Reported balance
After 2024-05-06 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-05-06 · Grant · Acquired 7,557 · Balance 7,557 F1: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. |
Filing footnotes · ownership attribution and instrument terms
F1: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service.
Rubius Therapeutics, Inc.
Report date October 14, 2019 · Filed October 17, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2019-10-14 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-10-14 · Exercise / conversion · Acquired 7,500 · Balance 7,500 Row 2 · 2019-10-14 · Sale · Disposed 7,500 · Balance 0 F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.21 to $8.79, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.15 · Expires 2025-02-04 | Direct | 120,000 |
Reported balance
After 2019-10-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-10-14 · Exercise / conversion · Disposed 7,500 · Balance 120,000 F3: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.21 to $8.79, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F3: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter.
SQZ Biotechnologies Co
Report date October 29, 2020 · Filed October 30, 2020
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 243,987 |
Reported balance
Holding disclosure · report date 2020-10-29 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 243,987 |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.81 · Expires 2026-10-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-29 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance Not disclosed F1: The option vests and becomes exercisable as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.02 · Expires 2018-03-04 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-29 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance Not disclosed F2: The option vests and becomes exercisable as to 25% of the underlying securities on January 23, 2019 and in 36 equal monthly installments thereafter. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.59 · Expires 2029-02-18 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2020-10-29 · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · Balance Not disclosed F3: The option vests and becomes exercisable as to 25% of the underlying securities on February 1, 2020 and in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable as to 25% of the underlying securities on October 11, 2017 and in 36 equal monthly installments thereafter.
F2: The option vests and becomes exercisable as to 25% of the underlying securities on January 23, 2019 and in 36 equal monthly installments thereafter.
F3: The option vests and becomes exercisable as to 25% of the underlying securities on February 1, 2020 and in 36 equal monthly installments thereafter.
Seer, Inc.
Report date July 28, 2026 · Filed July 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 821,025 |
Reported balance
After 2026-07-28 transaction · row 1
1 source rowRow 1 · 2026-07-28 · Grant · Acquired 16,500 · Balance 821,025 F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.14 · Expires 2036-07-28 | Direct | 25,000 |
Reported balance
After 2026-07-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-07-28 · Grant · Acquired 25,000 · Balance 25,000 F2: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
F2: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 28, 2026 Filed Jul 30, 2026 20:07 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $2.14 | $0.00 |
DisclosureSEC source: 0001239757-26-000002 · form4-07302026_080717.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Class A Common Stock · 25,000 shares Expires 2036-07-28 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| July 28, 2026 Filed Jul 30, 2026 20:07 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 16,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001239757-26-000002 · form4-07302026_080717.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 821,025 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 28, 2027 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 20:10 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 30,500 | $0.00 Strike: $2.18 | $0.00 |
DisclosureSEC source: 0001415889-25-019571 · form4-07092025_080719.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,500 Underlying: Class A Common Stock · 30,500 shares Expires 2035-07-07 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) July 7, 2026 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| July 07, 2025 Filed Jul 9, 2025 20:10 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 20,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-019571 · form4-07092025_080719.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 804,525 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) July 7, 2026 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 12, 2024 Filed Jun 14, 2024 20:25 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 58,178 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-016912 · form4-06142024_080624.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 784,025 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 12, 2025 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 06, 2024 Filed May 7, 2024 20:51 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 7,557 | $0.00 Strike: $122.13 | $0.00 |
DisclosureSEC source: 0001127602-24-014459 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,557 Underlying: Common Stock · 7,557 shares Expires 2034-05-06 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 6, 2025, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 01:18 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 34,735 | $0.00 Strike: $4.33 | $0.00 |
DisclosureSEC source: 0001209191-23-038193 · doc4.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,735 Underlying: Class A Common Stock · 34,735 shares Expires 2033-06-14 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 14, 2023 Filed Jun 17, 2023 01:18 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 23,443 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038193 · doc4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 725,847 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 14, 2024 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 03, 2023 Filed May 5, 2023 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 6,134 | $0.00 Strike: $130.14 | $0.00 |
DisclosureSEC source: 0001127602-23-014678 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,134 Underlying: Common Stock · 6,134 shares Expires 2033-05-03 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of May 3, 2024, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:07 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 14,846 | Not disclosed Strike: $10.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021379 · form4.xml · derivative · entry 4 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F5 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:07 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021379 · form4.xml · derivative · entry 3 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F4 · derivative.exercise_date: The option vested in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:07 UTC | Korro Bio, Inc. FREQ · Entity 6388 | Disposition to issuerStock Option · Derivative | 14,846 | Not disclosed Strike: $18.63 | Not disclosed |
DisclosureSEC source: 0001127602-22-021379 · form4.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 14,846 shares Expires 2030-06-10 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F3 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| August 17, 2022 Filed Aug 19, 2022 20:07 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | Not disclosed Strike: $2.14 | Not disclosed |
DisclosureSEC source: 0001127602-22-021379 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2030-06-10 F2 · price: The transaction reported herein reflects a one-time stock option repricing that became effective on August 17, 2022 and is being reported in this manner solely to comply with the technical reporting requirements under Section 16(a) of the Securities Exchange Act of 1934, as amended. There have been no other changes to the terms of these options. F1 · derivative.exercise_date: The option vested in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| June 21, 2022 Filed Jun 23, 2022 20:12 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $1.17 | $0.00 |
DisclosureSEC source: 0001127602-22-018032 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2032-06-20 F1 · derivative.exercise_date: The option vests in full on the earlier of June 21, 2023 or the day immediately prior to the company's 2023 annual meeting of shareholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:42 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 29,640 | $0.00 Strike: $7.33 | $0.00 |
DisclosureSEC source: 0001209191-22-038112 · doc4.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,640 Underlying: Class A Common Stock · 29,640 shares Expires 2032-06-15 F2 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 22:42 UTC | Seer, Inc. SEER · Entity 6717 | GrantClass A Common Stock | 9,945 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-038112 · doc4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,404 F1 · shares: The reported shares are represented by restricted stock units, or RSUs, which vest on the earlier of (i) June 15, 2023 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2022 Filed Feb 3, 2023 21:34 UTC | Moderna, Inc. MRNA · Entity 2025 | GiftCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-003341 · form5.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,466,961 F1 · price: The reported disposition represents a bona fide charitable gift made by the reporting person. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 5,415 | $0.00 Strike: $142.52 | $0.00 |
DisclosureSEC source: 0001127602-22-012860 · form4.xml · derivative · entry 6 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,415 Underlying: Common Stock · 5,415 shares Expires not disclosed F3 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F3 · derivative.expiration_date: This option will become fully vested and exercisable on the earlier of April 28, 2023, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012860 · form4.xml · derivative · entry 5 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 703 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award vested in full on April 28, 2022. Read SEC document |
| April 28, 2022 Filed May 2, 2022 20:45 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 703 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-012860 · form4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,467,664 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:44 UTC | Seer, Inc. SEER · Entity 6717 | ConversionClass B Common Stock · Derivative | 327,102 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-003127 · doc4.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 327,102 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Class B Common Stock is convertible at any time into Class A Common Stock on a one-to-one basis at the reporting person's election and has no expiration date. F1 · derivative.exercise_date: Each share of Class B Common Stock is convertible at any time into Class A Common Stock on a one-to-one basis at the reporting person's election and has no expiration date. F1 · derivative.expiration_date: Each share of Class B Common Stock is convertible at any time into Class A Common Stock on a one-to-one basis at the reporting person's election and has no expiration date. Read SEC document |
| January 10, 2022 Filed Jan 12, 2022 23:44 UTC | Seer, Inc. SEER · Entity 6717 | ConversionClass A Common Stock | 327,102 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-003127 · doc4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 692,459 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Class B Common Stock is convertible at any time into Class A Common Stock on a one-to-one basis at the reporting person's election and has no expiration date. Read SEC document |
| June 17, 2021 Filed Jun 21, 2021 20:34 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $10.14 | $0.00 |
DisclosureSEC source: 0001127602-21-020416 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2031-06-16 F1 · derivative.exercise_date: The option vests in full on the earlier of June 17, 2022 or the day immediately prior to the company's 2022 annual meeting of shareholders. Read SEC document |
| June 17, 2021 Filed Jun 22, 2021 22:32 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $33.74 | $0.00 |
DisclosureSEC source: 0001209191-21-042507 · doc4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Class A Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: Shares subject to the option vest on the earlier of (i) June 17, 2022 or (ii) the day prior to the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantRestricted Stock Units · Derivative | 703 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-014774 · form4.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 Underlying: Common Stock · 703 shares Expires not disclosed F2 · derivative.exercise_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. F2 · derivative.expiration_date: The shares subject to this restricted stock unit award will vest in full on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| April 28, 2021 Filed Apr 30, 2021 20:12 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 4,081 | $0.00 Strike: $178.68 | $0.00 |
DisclosureSEC source: 0001127602-21-014774 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,081 Underlying: Common Stock · 4,081 shares Expires 2031-04-28 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 28, 2022, or Moderna's next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 01:23 UTC | Seer, Inc. SEER · Entity 6717 | ConversionSeries A Convertible Preferred Stock · Derivative | 205,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017317 · wf-form4_160756340152405.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 205,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of Series A Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · derivative.exercise_date: Each share of Series A Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. F1 · derivative.expiration_date: Each share of Series A Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. Read SEC document |
| December 08, 2020 Filed Dec 10, 2020 01:23 UTC | Seer, Inc. SEER · Entity 6717 | ConversionClass A Common Stock | 205,831 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-20-017317 · wf-form4_160756340152405.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 365,357 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of Series A Convertible Preferred Stock automatically converted into Class A Common Stock on a one-to-one basis immediately prior to the completion of the Issuer's initial public offering of Class A Common Stock and had no expiration date. Read SEC document |
| December 03, 2020 Filed Dec 12, 2020 02:11 UTC | Seer, Inc. SEER · Entity 6717 | GrantStock Option (right to buy) · Derivative | 18,691 | $0.00 Strike: $19.00 | $0.00 |
DisclosureSEC source: 0001628280-20-017430 · wf-form4_160773906729638.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,691 Underlying: Class A Common Stock · 18,691 shares Expires 2020-12-03 F1 · derivative.exercise_date: Shares subject to the option vest in 36 equal monthly installments beginning on January 3, 2021. Read SEC document |
| November 17, 2020 Filed Nov 19, 2020 22:55 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GiftCommon Stock | 56,912 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-029622 · form4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,326 Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 11:24 UTC | Korro Bio, Inc. FREQ · Entity 6388 | GrantStock Option · Derivative | 14,846 | $0.00 Strike: $18.63 | $0.00 |
DisclosureSEC source: 0001127602-20-019480 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,846 Underlying: Common Stock · 14,846 shares Expires 2030-06-10 F1 · derivative.exercise_date: The option vests in full on the earlier of June 11, 2021 or the day immediately prior to the company's 2021 annual meeting of shareholders. Read SEC document |
| May 05, 2020 Filed May 6, 2020 23:31 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionSeries A-1/A Convertible Preferred Stock · Derivative | 23,057 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012170 · doc4.xml · derivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 668 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.exercise_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. F1 · derivative.expiration_date: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. Read SEC document |
| May 05, 2020 Filed May 6, 2020 23:31 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | ConversionCommon Stock | 668 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-20-012170 · doc4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,167 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of preferred stock was automatically converted into 0.0289998 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date. Read SEC document |
| April 30, 2020 Filed May 1, 2020 22:36 UTC | Lyra Therapeutics, Inc. LYRA · Entity 46837 | GrantStock Option · Derivative | 14,500 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0000899243-20-011748 · doc4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Underlying: Common Stock · 14,500 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option vests and becomes exercisable in 36 equal monthly installments occurring on the completion of each successive month of the Reporting Person's service to the Issuer following April 30, 2020. Read SEC document |
| April 29, 2020 Filed Apr 30, 2020 22:00 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 18,270 | $0.00 Strike: $46.37 | $0.00 |
DisclosureSEC source: 0001127602-20-014908 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,270 Underlying: Common Stock · 18,270 shares Expires 2030-04-29 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of April 29, 2021, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| October 14, 2019 Filed Oct 17, 2019 06:01 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001104659-19-054477 · a4.xml · derivative · entry 3 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 7,500 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter. Read SEC document |
| October 14, 2019 Filed Oct 17, 2019 06:01 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 7,500 | $8.52 | $63,874.50 |
DisclosureSEC source: 0001104659-19-054477 · a4.xml · nonDerivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.21 to $8.79, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 14, 2019 Filed Oct 17, 2019 06:01 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 7,500 | $0.15 | $1,125.00 |
DisclosureSEC source: 0001104659-19-054477 · a4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 16:14 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001104659-19-040757 · a4.xml · derivative · entry 3 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,500 Underlying: Common Stock · 7,500 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 16:14 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 7,500 | $14.94 | $112,048.50 |
DisclosureSEC source: 0001104659-19-040757 · a4.xml · nonDerivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.70 to $15.42, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| July 15, 2019 Filed Jul 17, 2019 16:14 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 7,500 | $0.15 | $1,125.00 |
DisclosureSEC source: 0001104659-19-040757 · a4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 20:16 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 54,660 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001127602-19-023017 · form4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,660 Underlying: Common Stock · 54,660 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| May 23, 2019 Filed May 28, 2019 19:58 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $16.27 | $0.00 |
DisclosureSEC source: 0001104659-19-032120 · a4.xml · derivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-05-22 F1 · derivative.exercise_date: This option shall vest in full on the earlier of (i) the one year anniversary of the grant date or (ii) the date of the next annual meeting of stockholders following the grant date, subject to the recipient's continued service. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:42 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001104659-19-022064 · a4.xml · derivative · entry 3 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Stock · 7,500 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:42 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 7,500 | $17.57 | $131,799.00 |
DisclosureSEC source: 0001104659-19-022064 · a4.xml · nonDerivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.20 to $18.20, inclusive. The Reporting Person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 15, 2019 Filed Apr 17, 2019 20:42 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 7,500 | $0.15 | $1,125.00 |
DisclosureSEC source: 0001104659-19-022064 · a4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 14, 2019 Filed Jan 18, 2019 16:36 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $0.15 | $0.00 |
DisclosureSEC source: 0001104659-19-002512 · a4.xml · derivative · entry 3 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,500 Underlying: Common Stock · 7,500 shares Expires 2025-02-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of this option shall vest on December 5, 2015, then in 12 equal quarterly installments thereafter. Read SEC document |
| January 14, 2019 Filed Jan 18, 2019 16:36 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | SaleCommon Stock | 7,500 | $14.59 | $109,443.75 |
DisclosureSEC source: 0001104659-19-002512 · a4.xml · nonDerivative · entry 2 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $14.02 to $15.02, inclusive. The reporting person undertakes to provide to Rubius Therapeutics, Inc., any security holder of Rubius Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| January 14, 2019 Filed Jan 18, 2019 16:36 UTC | Rubius Therapeutics, Inc. RUBY · Entity 116417 | Exercise / conversionCommon Stock | 7,500 | $0.15 | $1,125.00 |
DisclosureSEC source: 0001104659-19-002512 · a4.xml · nonDerivative · entry 1 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 21:27 UTC | Moderna, Inc. MRNA · Entity 2025 | ConversionSeries G Preferred Stock · Derivative | 4,559 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-18-030869 · doc4.xml · derivative · entry 5 LANGER ROBERT · CIK 0001239757 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,559 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · price: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: The Series G Preferred Stock (the "Preferred Stock") converted into Common Stock based on an applicable conversion ratio of 0.45872 upon the closing of the Issuer's initial public offering on December 11, 2018. The Preferred Stock had no expiration date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.